Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Immune Checkpoint Inhibitor-Associated Pericarditis.

Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL.

J Thorac Oncol. 2019 Jun;14(6):1102-1108. doi: 10.1016/j.jtho.2019.02.026. Epub 2019 Mar 7.

PMID:
30851443
2.

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).

Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA.

J Immunother Cancer. 2019 Mar 8;7(1):65. doi: 10.1186/s40425-019-0540-1.

3.

Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry.

Carvajal-Hausdorf DE, Patsenker J, Stanton KP, Villarroel-Espindola F, Esch A, Montgomery RR, Psyrri A, Kalogeras KT, Kotoula V, Foutzilas G, Schalper KA, Kluger Y, Rimm DL.

Clin Cancer Res. 2019 May 15;25(10):3054-3062. doi: 10.1158/1078-0432.CCR-18-2599. Epub 2019 Feb 22.

PMID:
30796036
4.

Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer.

Altan M, Kidwell KM, Pelekanou V, Carvajal-Hausdorf DE, Schalper KA, Toki MI, Thomas DG, Sabel MS, Hayes DF, Rimm DL.

NPJ Breast Cancer. 2018 Dec 10;4:40. doi: 10.1038/s41523-018-0095-1. eCollection 2018.

5.

Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.

Gupta S, Mani NR, Carvajal-Hausdorf DE, Bossuyt V, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL.

Lab Invest. 2018 Aug;98(8):1076-1083. doi: 10.1038/s41374-018-0064-1. Epub 2018 Jun 1.

6.

An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients.

Moore LM, Wilkinson R, Altan M, Toki M, Carvajal-Hausdorf DE, McGuire J, Ehrlich BE, Rimm DL.

NPJ Breast Cancer. 2018 Mar 12;4:6. doi: 10.1038/s41523-018-0057-7. eCollection 2018.

7.

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.

Carvajal-Hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL.

J Immunother Cancer. 2017 Oct 17;5(1):81. doi: 10.1186/s40425-017-0285-7.

8.

Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.

Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL.

Breast Cancer Res. 2017 Sep 25;19(1):109. doi: 10.1186/s13058-017-0898-2. No abstract available.

9.

High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence.

Wasserman BE, Carvajal-Hausdorf DE, Ho K, Wong W, Wu N, Chu VC, Lai EW, Weidler JM, Bates M, Neumeister V, Rimm DL.

Lab Invest. 2017 Dec;97(12):1521-1526. doi: 10.1038/labinvest.2017.93. Epub 2017 Sep 11.

10.

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.

Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL.

Breast Cancer Res. 2017 Aug 7;19(1):91. doi: 10.1186/s13058-017-0884-8. Erratum in: Breast Cancer Res. 2017 Sep 25;19(1):109.

11.

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.

Carvajal-Hausdorf DE, Schalper KA, Bai Y, Black J, Santin AD, Rimm DL.

Gynecol Oncol. 2017 Apr;145(1):154-158. doi: 10.1016/j.ygyno.2017.02.002. Epub 2017 Feb 11.

12.

Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.

Rehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V, Mani NL, McLaughlin J, Schalper KA, Rimm DL.

Mod Pathol. 2017 Mar;30(3):340-349. doi: 10.1038/modpathol.2016.186. Epub 2016 Nov 11.

13.

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.

Toki MI, Carvajal-Hausdorf DE, Altan M, McLaughlin J, Henick B, Schalper KA, Syrigos KN, Rimm DL.

J Thorac Oncol. 2016 Nov;11(11):1901-1911. doi: 10.1016/j.jtho.2016.06.025. Epub 2016 Jul 20.

14.

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.

Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL.

Clin Cancer Res. 2017 Jan 15;23(2):370-378. doi: 10.1158/1078-0432.CCR-16-0150. Epub 2016 Jul 20.

15.

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL.

JAMA Oncol. 2016 Jan;2(1):46-54. doi: 10.1001/jamaoncol.2015.3638. Erratum in: JAMA Oncol. 2016 Jan;2(1):146.

16.

Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL.

J Natl Cancer Inst. 2015 May 19;107(8). pii: djv136. doi: 10.1093/jnci/djv136. Print 2015 Aug.

17.

Objective measurement and clinical significance of TILs in non-small cell lung cancer.

Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL.

J Natl Cancer Inst. 2015 Feb 3;107(3). pii: dju435. doi: 10.1093/jnci/dju435. Print 2015 Mar.

18.

Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic.

Carvajal-Hausdorf DE, Schalper KA, Neumeister VM, Rimm DL.

Lab Invest. 2015 Apr;95(4):385-96. doi: 10.1038/labinvest.2014.157. Epub 2014 Dec 15. Review.

19.

Possible role of hemichannels in cancer.

Schalper KA, Carvajal-Hausdorf D, Oyarzo MP.

Front Physiol. 2014 Jun 27;5:237. doi: 10.3389/fphys.2014.00237. eCollection 2014.

Supplemental Content

Loading ...
Support Center